Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, J.
(Chest. 1964;46:545-547.)
© 1964 American College of Chest Physicians

A New Pneumokinetic Drug (Dimefline) in the Treatment of Bronchial Asthma

Jerome Miller M.D.1

1 Chief of Allergy, Union Health Center, AFL Medical Center

Dimefline, a potent pneumokinetic agent, has been effectively used orally and by injection in patients suffering from bronchial asthma with or without emphysema.

The injectable has been used with immediate dramatic results for symptomatic relief of the acute asthmatic attack with virtual absence of sympathomimetic effects as seen with epinephrine.

Dimefline is an effective pharmacologic agent capable of increasing the depth without increasing the rate of respiration.

It is an excellent drug for aborting an acute asthmatic attack, and is a good maintenance drug in the treatment of bronchial asthma, particularly when given in association with a bronchodilator.

Side effects were mild, transitory and controlled by adjustment of dosage.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1964 by the American College of Chest Physicians.